THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company presented key efficacy data at the American Academy of Neurology (AAN) 62nd Annual Meeting held in Toronto, Canada.
